NCT02907268View on ClinicalTrials.gov

Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Facial Rhytids
Interventions
DRUG

onabotulinumtoxinA

OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.

DRUG

abobotulinumtoxinA

AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.

All Listed Sponsors
lead

ICLS Dermatology & Plastic Surgery

OTHER

NCT02907268 - Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study | Biotech Hunter | Biotech Hunter